Thomasville National Bank Reduces Position in Kenvue Inc. $KVUE

Thomasville National Bank trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 94.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,494 shares of the company’s stock after selling 706,813 shares during the period. Thomasville National Bank’s holdings in Kenvue were worth $657,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Renaissance Capital LLC boosted its holdings in shares of Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after buying an additional 48,267 shares during the last quarter. Farther Finance Advisors LLC raised its position in Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after acquiring an additional 16,164 shares during the period. Arlington Partners LLC purchased a new position in shares of Kenvue during the 2nd quarter worth $2,110,000. AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Kenvue during the 1st quarter valued at $1,725,000. Finally, Cornell Pochily Investment Advisors Inc. grew its position in shares of Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after acquiring an additional 19,609 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.5%

Shares of KVUE stock opened at $17.02 on Friday. The company’s fifty day simple moving average is $16.29 and its two-hundred day simple moving average is $18.87. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The stock has a market cap of $32.61 billion, a P/E ratio of 22.69 and a beta of 0.60. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same period in the previous year, the firm posted $0.28 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Insiders Place Their Bets

In other Kenvue news, Director Jeffrey C. Smith purchased 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.68% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $22.50 to $22.00 in a report on Friday, September 26th. Jefferies Financial Group dropped their price target on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.